Use of genetic mouse models in the study of diabetic nephropathy

被引：29

作者：

Allen T.J. ^{[1
]}

Cooper M.E. ^{[1
]}

Lan H.Y. ^{[1
]}

机构：

[1] Department of Medicine, Baylor College of Medicine, Houston, TX 77030, One Baylor Plaza

来源：

Current Atherosclerosis Reports | 2004年 / 6卷 / 3期

关键词：

Diabetic Nephropathy; Diabetic Mouse; Connective Tissue Growth Factor; Albumin Excretion Rate; Diabetic Kidney Disease;

D O I：

10.1007/s11883-004-0032-7

中图分类号：

学科分类号：

摘要：

The study of experimental diabetic nephropathy in rodent models has led to many changes in the clinical management of human diabetic nephropathy. With the development of technology to generate knockout and transgenic animals, the mouse has become a favored species in medical research. There are several genetic mouse models of diabetes, with the majority being models of type 2 diabetes mellitus. These include the hypoinsulinemic non-obese diabetic mouse, the Kkay mouse, the New Zealand obese mouse, the hyperinsulinemic ob/ob mouse, and the different strains of obese hyperinsulinemic db/db mouse. Each of these models displays some renal changes, but by far the best model of renal disease and the one that is the most studied is the db/db mouse. The db/db mouse displays substantial glomerular pathology, including mesangial matrix expansion and modest albuminuria. It has been reported that the db/db mouse has a decline in creatinine clearance after 5 months of age, but more specific approaches are warranted to confirm these findings. A number of intervention studies show renoprotection in this model. Although mice have many advantages, such as being able to be cross-bred with genetically manipulated animals, in many ways they are not very similar to humans, and in some respects the rat may be a better choice, particularly in relation to some features of end-organ injury. Copyright © 2004 by Current Science Inc.

引用

页码：197 / 202

页数：5

共 51 条

[1] Cooper M.E., Allen T.J., Macmillan P.A., Et al., Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat, Diabetologia, 32, pp. 326-328, (1989)
[2] Zatz R., Dunn B.R., Meyer T.W., Brenner B., Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension, J. Clin. Invest., 77, pp. 1925-1930, (1986)
[3] Anders H., Schlondorff D., Murine models of renal disease: Possibilities and problems in studies using mutant mice, Exp. Nephrol., 8, pp. 181-193, (2000)
[4] Cooper M.E., Pathogenesis, prevention, and treatment of diabetic nephropathy, Lancet, 352, pp. 213-219, (1998)
[5] Cooper M.E., Gilbert R.E., Allen T.J., Experimental diabetic nephropathy, Lessons from Animal Diabetes, pp. 207-223, (1996)
[6] Velasquez M.T., Kimmel P.L., Michaelis O.E., Animal models of spontaneous diabetic kidney disease, FASEB J., 4, pp. 2850-2859, (1990)
[7] Doi T., Hattori M., Agodoa L.Y., Et al., Glomerular lesions in nonobese diabetic mouse: Before and after the onset of hyperglycemia, Lab. Invest., 63, pp. 204-212, (1990)
[8] Yang C.W., Hattori M., Vlassara H., Et al., Overexpression of transforming growth factor-beta 1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice, J. Am. Soc. Nephrol., 5, pp. 1610-1617, (1995)
[9] Liu Z.H., Striker L.J., Hattori M., Et al., Localization of glutamic acid decarboxylase in the kidneys of nonobese diabetic mice, Nephron, 72, pp. 662-666, (1996)
[10] Sharma K., Ziyadeh F.N., Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator, Diabetes, 44, pp. 1139-1146, (1995)

← 1 2 3 4 5 6 →